Cite
HARVARD Citation
Alexander, T. et al. (2015). The proteasome inhibitior bortezomib depletes plasma cells and ameliorates clinical manifestations of refractory systemic lupus erythematosus. Annals of the rheumatic diseases. 74 (7), pp. 1474-1478. [Online].